Summary
Point-of-care testing (POCT), also known as bedside testing, near-patient testing, or decentralized laboratory testing, is an emerging specialty within in vitro diagnostics (IVD). POCT is one of the most rapidly growing areas in IVD, both due to the drive to increase efficiency and therefore improve patient care, and as a result of significant technological advances. Developments in fluid handling, microchip technology, and improved manufacturing processes are improving sensitivity and enabling miniaturization of point-of-care (POC) diagnostic platforms.
In recent years, manufacturers have worked to overthrow the image of poor sensitivity and unreliable results previously associated with POCT. Despite several recalls linked to erroneous results, there has been a significant improvement in analytic technologies, which in some cases match the performance of central laboratory testing. These tests have the potential to improve outcomes in primary and acute care by optimizing healthcare delivery to support more patient-centered approaches, and allow for more rapid treatment of patients. Along with the emergence of promising new POC technologies, and pressures to reduce cost and improve the quality of healthcare delivered, GlobalData anticipates the cardiac marker POC market is poised for growth during the forecast period.
This report focuses on the POC diagnostics market in the Asia-Pacific market (APAC: Japan, China, India, South Korea, and Australia). In this report, GlobalData evaluates the currently marketed POC products, identifies the unmet needs in each market, analyzes market dynamics, and provides an understanding of physicians’ adoption trends for different types of POC products. In order to successfully take advantage of the growing POC diagnostics market, manufacturers are required to adopt strategies that address the current unmet needs, and to concentrate on demonstrating the clinical value of their products, to drive physician adoption.
*This is an on-demand report and will be delivered within 4 working days (excluding weekends) of the purchase.
Highlights
Key Questions Answered
- What is the current and future cardiac marker rapid test and POC market outlook in the developed and emerging markets? What trends are affecting the APAC market?
- Which are the key, high growth markets that cardiac marker rapid test and POC manufacturers should expand into? Which markets are growing the fastest, and what are the top-selling products in each segment?
- What are the unmet needs with the current generation of cardiac marker rapid test and POC devices? How will emerging technologies fulfill these unmet needs?
- What clinical factors and technical specifications influence a physician to use one type of device over another? What is physician perception and market outlook for cardiac marker rapid test and POCT?
- What are the challenges and complications that have hindered widespread adoption?
- With developing the next-generation of devices, what aspects of the technology are device manufacturers focused on optimizing? How will new entrants impact the cardiac marker rapid test and POCT market?
Scope
- Overview of recent key industry events and analysis of their market impact.
- Annualized total market revenue by type of device, procedure trends, and market outlooks by segment and by region through 2023
- Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement considerations, evaluating market access in each region covered in the report, and implications of the emerging technologies in the market.
- Pipeline analysis: Comprehensive data split across different stages of development, including a discussion of emerging trends and devices in development.
- Analysis of the current and future market competition in the APAC cardiac marker rapid test and POC market. Insightful review of the key industry drivers, barriers, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
- “What Physicians Think” quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.
Companies Mentioned
Abbott Point of Care
Alere
LSI Medience
Philips Healthcare
Radiometer Medical
Response Biomedical
Roche Diagnostics
Siemens Healthineers
Trinity Biotech
'
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Sales of Cardiac Marker POC and Rapid Tests
2.2 Market Opportunities
2.3 Key Players in the Cardiac Marker POCT Market
2.4 Cardiac Marker POCT Market Outlook
2.5 What Do Physicians Think?
3 Introduction
3.1 POC Diagnostics Overview
3.2 Catalyst
3.3 Related Reports
4 Market Opportunities
4.1 Unmet Needs
4.1.1 Improved Reliability of Tests Outside Controlled Testing Environments
4.1.2 Data Management
4.1.3 Evidence of Cost-Effectiveness or Improved Patient Outcomes
4.1.4 Markers for Myocardial Ischemia
4.2 Market Drivers
4.2.1 Fast Turnaround Time
4.2.2 Use of POC Troponin Testing in Pre-hospital Settings
4.2.3 Increased Uptake of D-Dimer Testing
4.2.4 CLIA-Waived Status for POCT
4.2.5 Rising Prevalence of Diseases
4.3 Market Barriers
4.3.1 Management of POCT
4.3.2 Disruption to Traditional Ways of Working
4.3.3 Competition with Laboratory Tests
4.3.4 Regulatory Compliance
4.3.5 Cost and Reimbursement
4.3.6 Low Uptake of Novel Biomarkers
5 Market Access
5.1 Reimbursement Trends
5.2 Regulatory Issues and Recalls
5.3 Mergers, Acquisitions, and Key Partnerships
6 Competitive Assessment
6.1 Company Share Analysis
6.2 Major Players
6.2.1 Abbott Point of Care
6.2.2 Alere
6.2.3 LSI Medience
6.2.4 Philips Healthcare
6.2.5 Radiometer Medical
6.2.6 Response Biomedical
6.2.7 Roche Diagnostics
6.2.8 Siemens Healthineers
6.2.9 Trinity Biotech
7 Pipeline Assessment
7.1 Overview
7.2 Troponin Tests
7.3 BNP Tests
7.4 Panel Tests
7.5 Other Biomarkers
8 Procedure Trends
8.1 Troponin Tests
8.2 B-Type Natriuretic Peptide Tests
8.3 Other Cardiac Marker Tests
9 Market Outlook
9.1 Market Segment Analysis
9.2 Australia
9.3 China
9.4 Japan
9.5 India
9.6 South Korea
10 Appendix
10.1 Bibliography
10.2 Abbreviations
10.3 Report Methodology
10.3.1 Overview
10.3.2 Coverage
10.3.3 Secondary Research
10.3.4 Forecasting Methodology
10.3.5 Primary Research - Key Opinion Leader Interviews
10.4 About the Authors
10.4.1 Analysts
10.4.2 Tyler Fletcher, Global Head of Medical Devices
10.5 About MediPoint
10.6 About GlobalData
10.7 Contact Us
10.8 Disclaimer
1.1 List of Tables
Table 1: Cardiac Marker Rapid Tests & POC Key Metrics, 2016-2023
Table 2: Advantages and Disadvantages of POCT
Table 3: Regulatory Issues and Recalls 2012-2016
Table 4: Mergers, Acquisitions, and Key Partnerships, 2015-2016
Table 5: Company Profile - Abbott Point of Care
Table 6: Abbott Point of Care Portfolio Assessment, 2016
Table 7: SWOT Analysis - Abbott Point of Care
Table 8: Company Profile - Alere
Table 9: Alere POC Portfolio Assessment, 2016
Table 10: SWOT Analysis - Alere
Table 11: Company Profile - LSI Medience
Table 12: LSI Medience POC Portfolio Assessment, 2016
Table 13: SWOT Analysis - LSI Medience
Table 14: Company Profile - Philips Healthcare
Table 15: Philips Healthcare POC Portfolio Assessment, 2016
Table 16: SWOT Analysis - Philips Healthcare
Table 17: Company Profile - Radiometer Medical
Table 18: Radiometer Medical POC Portfolio Assessment, 2016
Table 19: SWOT Analysis - Radiometer Medical
Table 20: Company Profile - Response Biomedical
Table 21: Response Biomedical POC Portfolio Assessment, 2016
Table 22: SWOT Analysis - Response Biomedical
Table 23: Company Profile - Roche Diagnostics
Table 24: Roche Diagnostics POC Portfolio Assessment, 2016
Table 25: SWOT Analysis - Roche Diagnostics
Table 26: Company Profile - Siemens Healthineers
Table 27: Siemens Healthineers POC Portfolio Assessment, 2016
Table 28: SWOT Analysis - Siemens Healthineers
Table 29: Company Profile - Trinity Biotech
Table 30: Trinity Biotech POC Portfolio Assessment, 2016
Table 31: SWOT Analysis - Trinity Biotech
Table 32: Key Troponin POCT Pipelines, 2016
Table 33: Key BNP POCT Pipelines, 2016
Table 34: Key Cardiac Panel POCT Pipelines, 2016
Table 35: Key Other Cardiac Marker POC and Rapid Test Pipelines, 2016
Table 36: Troponin POCT Volume (thousands) Forecast by Country, 2014-2023
Table 37: BNP POCT Volume (thousands) Forecast by Country, 2014-2023
Table 38: Other Cardiac Marker POCT Volume (thousands) Forecast by Country, 2014-2023
Table 39: APAC Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 40: APAC Cardiac Marker POCT Sales Forecast ($m) by Country, 2014-2023
Table 41: Australia Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 42: China Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 43: Japan Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 44: India Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 45: South Korea Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
1.2 List of Figures
Figure 1: Cardiac Marker POCT Market Share ($) by Country, 2016 and 2023
Figure 2: APAC and Rest of World Company Share Analysis, 2016
Figure 3: Troponin POCT Volume (thousands) Forecast by Region, 2014-2023
Figure 4: BNP POCT Volume (thousands) Forecast by Region, 2014-2023
Figure 5: Other Cardiac Marker POCT Volume (thousands) Forecast by Region, 2014-2023
Figure 6: Cardiac Marker POCT Sales Forecast ($m), 2014-2023
Figure 7: Cardiac Marker POCT Market Share ($) by Country, 2016
Figure 8: Australia Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 9: China Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 10: Japan Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 11: India Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 12: South Korea Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
